InterCure (INCR) Competitors

InterCure (NASDAQ:INCR) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

Which has more risk and volatility, INCR or IMAB?

InterCure has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Which has higher valuation and earnings, INCR or IMAB?

InterCure has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$96.61M	1.50	-$16.83M	$0.13	24.39
I-Mab	$3.89M	37.63	-$206.44M	N/A	N/A

Is INCR or IMAB more profitable?

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

Does the MarketBeat Community prefer INCR or IMAB?

I-Mab received 53 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 62.92% of users gave I-Mab an outperform vote.

Company	Underperform	Outperform
InterCure	Outperform Votes 3 100.00%	Underperform Votes No Votes
I-Mab	Outperform Votes 56 62.92%	Underperform Votes 33 37.08%

Does the media refer more to INCR or IMAB?

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 1.43 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Positive
I-Mab	Positive

Do institutionals & insiders hold more shares of INCR or IMAB?

8.3% of InterCure shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts rate INCR or IMAB?

I-Mab has a consensus price target of $12.25, indicating a potential upside of 562.13%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
I-Mab	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

I-Mab beats InterCure on 6 of the 10 factors compared between the two stocks.